Lifitegrast

Lifitegrast
Clinical data
Trade names Xiidra
AHFS/Drugs.com xiidra
Routes of
administration		 Eye drops
ATC code none
Legal status
Legal status
Identifiers
Synonyms SAR-1118
CAS Number 1025967-78-5
PubChem (CID) 11965427
ChemSpider 10139520
UNII 038E5L962W
KEGG D10374
ChEBI CHEBI:133023 YesY
ChEMBL CHEMBL2048028
Chemical and physical data
Formula C29H24Cl2N2O7S
Molar mass 615.48 g·mol−1
3D model (Jmol) Interactive image

Lifitegrast (trade name Xiidra) is a drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is applied in the form of eye drops.[1]

Adverse effects

Common side effects in clinical trials were eye irritation, discomfort, blurred vision, and dysgeusia (a distortion of the sense of taste).[2]

Pharmacology

Mechanism of action

Lifitegrast inhibits an integrin, lymphocyte function-associated antigen 1 (LFA-1), from binding to intercellular adhesion molecule 1 (ICAM-1). This mechanism down-regulates inflammation mediated by T lymphocytes.[1][3]

History

Lifitegrast was initially designed and developed by SARcode Bioscience[4] which was acquired by Shire in 2013,[5] who submitted a new drug application to the US Food and Drug Administration (FDA) in March 2015. The FDA granted Shire a priority review a month later, and requested additional clinical data, which were supplied in January 2016. The drug was finally approved on 11 July 2016.[6][7]

See also

References

  1. 1 2 Tauber, J (December 2015). "Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study". Ophthalmology. 122 (12): 2423–31. doi:10.1016/j.ophtha.2015.08.001. PMID 26365210.
  2. ↑ Drugs.com: Patient in formation for xiidra.
  3. ↑ Murphy, C. J.; Bentley, E; Miller, P. E.; McIntyre, K; Leatherberry, G; Dubielzig, R; Giuliano, E; Moore, C. P.; Phillips, T. E.; Smith, P. B.; Prescott, E; Miller, J. M.; Thomas, P; Scagliotti, R; Esson, D; Gadek, T; O'Neill, C. A. (2011). "The Pharmacologic Assessment of A Novel Lymphocyte Function-Associated Antigen-1 Antagonist (SAR 1118) for the Treatment of Keratoconjunctivitis Sicca in Dogs". Investigative ophthalmology & visual science. 52 (6): 3174–80. doi:10.1167/iovs.09-5078. PMID 21330663.
  4. ↑ Semba, Charles; Gadek, Thomas (2016). "Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease". Clinical Ophthalmology: 1083. doi:10.2147/OPTH.S110557.
  5. ↑ "Shire To Acquire Sarcode Bioscience, Expands Presence In Ophthalmology". 25 March 2013.
  6. ↑ "FDA Approves Shire's Xiidra". 11 July 2016.
  7. ↑ Drugs.com: Xiidra (lifitegrast) FDA Approval History
This article is issued from Wikipedia - version of the 9/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.